Cardiff Oncology, Inc. - CRDF STOCK NEWS

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, announced two abstracts to be presented at the AACR Annual Meeting 2021 from April 10-15, 2021. The first abstract focuses on the Expanded Access Program for their PLK1 inhibitor onvansertib in treating KRAS-mutant metastatic colorectal cancer, showing over 50% decrease in KRAS mutant allelic frequency in several patients. The second highlights preclinical studies on the synergy between onvansertib and abiraterone in treating prostate cancer. Full abstracts will be available online during the event.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, announced its presentation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9. Cardiff specializes in developing treatments for aggressive cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, with their investigational drug, onvansertib, being a key focus. The company will also hold one-on-one meetings with investors during the conference.

Cardiff Oncology (Nasdaq: CRDF) reported key highlights and financial results for Q4 and FY 2020, achieving significant clinical milestones. The company raised over $100 million, providing a solid financial foundation. Promising data from the mCRC program indicate onvansertib's potential, contributing to a 86% clinical benefit rate in evaluated patients. They plan to initiate a Phase 2 trial in PDAC in 2021 after receiving FDA clearance. Financially, cash reserves stood at $131 million, with increased R&D and SG&A expenses reflecting ongoing clinical endeavors.

On February 24, 2021, Cardiff Oncology (Nasdaq: CRDF) announced CEO Dr. Mark Erlander's participation in the Cowen 41st Annual Health Care Conference from March 1-4, 2021. He will join a panel discussion on GI Oncology and Pancreatic Cancer on March 2nd, from 9:50 to 10:50 am ET. Cardiff Oncology is focused on developing treatments for cancers with significant medical needs, particularly utilizing its investigational drug, onvansertib, for various cancers including KRAS-mutated colorectal cancer and pancreatic cancer.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, is set to present at the LifeSci Partners Precision Oncology Day on February 17, 2021. The presentation, led by CEO Mark Erlander, will focus on the company’s innovative cancer treatment, onvansertib, aimed at addressing high-need conditions like KRAS-mutated colorectal and pancreatic cancer. One-on-one meetings will also occur. A replay of the presentation will be available on their website post-event.

Cardiff Oncology (Nasdaq: CRDF) presented updated results from its Phase 2 trial targeting metastatic castrate-resistant prostate cancer (mCRPC) at the ASCO-GU symposium. The trial evaluated the combination of onvansertib, abiraterone, and prednisone, showing a significant increase in the disease control rate (DCR) from 29% to 63% when treatment days were optimized from 5 to 14. With 75% of patients in the optimized cohort achieving stable disease at 12 weeks, the trial appears poised to meet its primary endpoint of 30% DCR. The study's findings suggest potential for enhanced patient outcomes in this challenging cancer subtype.

Cardiff Oncology (Nasdaq: CRDF) announced FDA approval to begin a Phase 2 clinical trial for onvansertib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This trial will assess the combination of onvansertib, nanoliposomal irinotecan, leucovorin, and 5-FU as a second-line treatment for patients who failed prior gemcitabine therapy. Approximately 40 patients will be enrolled across six U.S. sites, including Mayo Clinic locations. The trial aims to evaluate safety and efficacy, with overall response rate as the primary endpoint.

On January 15, 2021, Cardiff Oncology (Nasdaq: CRDF) presented data on its investigational drug, onvansertib, at the ASCO-GI symposium. The Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC) confirmed the recommended Phase 2 dose at 15 mg/m². Notable outcomes included a 42% partial response rate and 67% of patients showing durable responses lasting over 6 months. Initial findings from the Expanded Access Program mirrored these results, with 66% of patients demonstrating tumor shrinkage. The trial involves collaboration with prominent cancer centers.

Cardiff Oncology (Nasdaq: CRDF) announced the immediate resignation of Dr. Thomas Adams as Executive Chairman and Chairman of the Board, effective December 21, 2020. Dr. Rodney Markin has been appointed as the new Chairman. The board expressed gratitude for Dr. Adams' twelve years of leadership, which facilitated the company's transition from molecular diagnostics to drug development. With ongoing clinical programs targeting KRAS-mutated colorectal cancer, castration-resistant prostate cancer, and acute myeloid leukemia, the company aims to enhance treatment options for patients in need.